Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · prpl@cc.nih.gov · 800-411-1222
Study leads
Bibiana Bielekova, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)